TheraRadar
← Back
Data updated: Jun 28, 2026

SIGMAPHARM LABS LLC

Generics

SIGMAPHARM LABS LLC is a generic drug manufacturer focused on Cardiovascular, Infectious Disease, Immunology.

2009
Since
17
Drugs
-
Trials
0
New Drugs (2yr)
Modality:

SIGMAPHARM LABS LLC's Key Drugs

SIGMAPHARM LABS LLC's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

SIGMAPHARM LABS LLC's Recent FDA Approvals

New NDA/BLA approvals for SIGMAPHARM LABS LLC over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

SIGMAPHARM LABS LLC's Therapeutic Areas

SIGMAPHARM LABS LLC's approved drugs and pipeline span 4 therapeutic areas, led by Cardiovascular and Infectious Disease, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 33%
2 drugs
Infectious Disease 33%
2 drugs
Immunology 17%
1 drugs
Respiratory 17%
1 drugs

SIGMAPHARM LABS LLC's Top Competitors

SIGMAPHARM LABS LLC's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and LEDERLE. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

SIGMAPHARM LABS LLC Pipeline Snapshot

Active clinical trials for SIGMAPHARM LABS LLC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling